Cargando…

Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience

BACKGROUND: Imatinib mesylate is the cornerstone therapy in the management of chronic myeloid leukemia (CML). Monitoring of adverse drug reactions (ADRs) of imatinib in our patients is very important to ensure their safety. Aims and Objectives: The current study aims to monitor ADRs encountered in C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swain, Trupti Rekha, Goutam, Siddhartha, Jena, Rabindra Kumar, Rout, Niranjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846910/ https://www.ncbi.nlm.nih.gov/pubmed/36537404 http://dx.doi.org/10.4103/ijp.ijp_844_21

Ejemplares similares

L-asparaginase-induced abnormality in plasma glucose level in patients of acute lymphoblastic leukemia admitted to a tertiary care hospital of Odisha
por: Panigrahi, Mousumee, et al.
Publicado: (2016)

Clinical significance of P53 and Bcl-2 in acute myeloid leukemia patients of Eastern India
por: Sahu, Geetaram, et al.
Publicado: (2011)

Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study
por: Francis, Jose, et al.
Publicado: (2015)

Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study: Erratum
Publicado: (2015)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia
por: Yusoff, Yuslina Mat, et al.
Publicado: (2018)

Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha
por: Panigrahi, Mousumee, et al.
Publicado: (2020)

Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib
por: Chhikara, Sunita, et al.
Publicado: (2018)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Pricing and components analysis of some key essential pediatric medicine in Odisha state
por: Samal, Satyajit, et al.
Publicado: (2017)

Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase
por: Mughal, Tariq I, et al.
Publicado: (2010)

Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
por: Conchon, Monika, et al.
Publicado: (2011)

Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
por: Kok, Chung H., et al.
Publicado: (2023)

Comparison of effectiveness and safety of Iranian-made vs. Indian-made imatinib in treatment of chronic myeloid leukemia
por: Moshfeghi, Kamran, et al.
Publicado: (2013)

Factors Influencing Adherence to Imatinib in Indian Chronic Myeloid Leukemia Patients: A Cross-Sectional Study
por: Kapoor, Jyotsna, et al.
Publicado: (2015)

MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations
por: San José-Enériz, Edurne, et al.
Publicado: (2009)

Molecular Response to Imatinib and Its Correlation with mRNA Expression Levels of Imatinib Influx Transporter (OCT1) in Indian Chronic Myeloid Leukemia Patients
por: Chhikara, S, et al.
Publicado: (2017)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

Nonadherence to anti-HIV medication is associated with higher level of anxiety: Experience from a tertiary care hospital of Odisha
por: Panigrahi, Mousumee, et al.
Publicado: (2015)

Chronic myeloid leukemia in the Imatinib era – Compilation of Indian data from 22 centers involving 8115 patients
por: Parikh, Purvish, et al.
Publicado: (2013)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Cutaneous adverse drug reaction profile in a tertiary care out patient setting in Eastern India
por: Saha, Abanti, et al.
Publicado: (2012)

Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia
por: Kim, Kibum, et al.
Publicado: (2019)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

Has the Public Health System Provided Adequate Financial Risk Protection for Child Birth Conditions – Evidences From an Eastern Indian State
por: Rout, Sarit Kumar, et al.
Publicado: (2018)

Comparison of Dasatinib- and Imatinib-Related Cardiotoxic Adverse Events in Japanese Patients With Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumor
por: Motokawa, Tetsufumi, et al.
Publicado: (2021)

Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study
por: Goni, Deepak, et al.
Publicado: (2023)

Incidence of atazanavir- associated adverse drug reactions in second -line drugs treated south Indian HIV-1 infected patients
por: Subashini, Dhakshinamoorthy, et al.
Publicado: (2016)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
por: Bilajac, Esma, et al.
Publicado: (2022)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec(®), Gleevec™)
por: Henkes, Martin, et al.
Publicado: (2008)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
por: Martin, Jovita, et al.
Publicado: (2011)

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
por: Bitencourt, Roberta, et al.
Publicado: (2011)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_nb2t0gq9pmf27mqug6c8sa9bhq